Good morning, everyone and welcome to another working week. We hope the weekend respite was relaxing and invigorating, despite the ongoing tumult, because that oh-so-predictable routine of Zoom meetings, Skype calls, and deadlines has returned. To cope, yes, we are firing up the coffee kettle and brewing another cup of stimulation. Our choice today is maple bourbon. Feel free to join us. Remember, no prescription is required. Meanwhile, here are a few tidbits. We hope your day goes well and you conquer the world. …

FDA Commissioner Stephen Hahn on Sunday maintained that authorization of the Pfizer (PFE) Covid-19 vaccine was made as quickly as possible, despite claims to the contrary by President Donald Trump, ABC News tells us. “We do not feel that this could have been out a week earlier,” Hahn told ABC’s “This Week.” “We went through our process. We promised the American people that we would do a thorough review of the application and that’s what we did. We followed our process.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What’s included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.


Leave a Reply

ArabicChinese (Simplified)EnglishFrenchGermanItalianJapanesePortugueseRussianSpanish

[mc4wp_form id="449"]